Form 4: Cue Biopharma CEO Sells Shares
Insider Transaction (Form 4)
Shao-Lee Lin, Chief Executive Officer and a Director of Cue Biopharma, Inc., sold 58,258 shares of common stock on August 12, 2026.
Summary
- Option exercise/conversion: acquired 109,179 Common Stock on August 12, 2026; holds 764,253 after (Direct).
- Open-market sale: disposed of 34,225 Common Stock at $26.99 ($923,733) on August 12, 2026; holds 730,028 after (Direct).
- Open-market sale: disposed of 5,775 Common Stock at $27.75 ($160,256) on August 12, 2026; holds 724,253 after (Direct).
- Open-market sale: disposed of 5,423 Common Stock at $27.19 ($147,451) on August 13, 2026; holds 718,830 after (Direct).
- Open-market sale: disposed of 2,375 Common Stock at $28.11 ($66,761) on August 13, 2026; holds 716,455 after (Direct).
- Open-market sale: disposed of 10,460 Common Stock at $29.48 ($308,361) on August 13, 2026; holds 705,995 after (Direct).
- Option exercise/conversion: disposed of 109,179 Common Stock on August 12, 2026; holds 218,358 after (Direct).
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $1,606,562 of stock on the open market.
Insider Transactions
Shao-Lee Lin — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-12 | Option exercise/conversion | Common Stock | 109,179 | — | — | 764,253 |
| 2026-08-12 | Open-market sale | Common Stock | 34,225 | $27 | $923.7K | 730,028 |
| 2026-08-12 | Open-market sale | Common Stock | 5,775 | $28 | $160.3K | 724,253 |
| 2026-08-13 | Open-market sale | Common Stock | 5,423 | $27 | $147.5K | 718,830 |
| 2026-08-13 | Open-market sale | Common Stock | 2,375 | $28 | $66.8K | 716,455 |
| 2026-08-13 | Open-market sale | Common Stock | 10,460 | $29 | $308.4K | 705,995 |
| 2026-08-12 | Option exercise/conversion | Common Stock | 109,179 | — | — | 218,358 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-12 | Option exercise/conversion (109,179 shares) |
| 2026-08-12 | Open-market sale (34,225 shares) |
| 2026-08-12 | Open-market sale (5,775 shares) |
| 2026-08-13 | Open-market sale (5,423 shares) |
| 2026-08-13 | Open-market sale (2,375 shares) |
| 2026-08-13 | Open-market sale (10,460 shares) |
| 2026-08-12 | Option exercise/conversion (109,179 shares) |
Keywords
insider transaction, Form 4, CUE, Cue Biopharma, Inc., bearish, Shao-Lee Lin
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.